کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8486012 | 1551760 | 2018 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
NSPGMTFMDUSDADPCFFBFMDVDPVCVBVNTAPHISVirus neutralization test - آزمون خنثی سازی ویروسAdjuvant - ادجوانت، یاورFoot-and-mouth disease - تب برفکی، بیماری دهان و پاUnited States Department of Agriculture - دپارتمان کشاورزی ایالات متحدهDIVA - دیواdays post-vaccination - روز بعد از واکسیناسیونnonstructural protein - غلظت پروتئینFoot-and-mouth disease virus - ویروس آنفلوآنزای مرغیVaccine efficacy - کارآیی واکسن
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24â¯+â¯ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14â¯days post-vaccination (dpv) than steers vaccinated with the active ingredient alone. In the second study, vaccination with AdtA24 formulated in ENABL® at the same dose used in the first study, followed by FMDV A24/Cruzeiro/BRA/55 challenge on 7 or 14 dpv, prevented clinical FMD in all steers and conferred 90% protection against viremia. In addition, post-challenge FMDV titers in nasal samples from vaccinated steers compared to unvaccinated steers were significantly reduced. In both studies, none of the AdtA24 vaccinated steers developed antibodies to the FMDV non-structural proteins prior to challenge with FMDV, indicative of the capacity to differentiate infected from vaccinated animals (DIVA). These results demonstrate that administration of AdtA24 formulated in ENABL® adjuvant lowered the protective dose and prevented clinical FMD following exposure of vaccinated steers to virulent FMDV at 7 or 14 dpv.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 36, Issue 8, 14 February 2018, Pages 1078-1084
Journal: Vaccine - Volume 36, Issue 8, 14 February 2018, Pages 1078-1084
نویسندگان
José Barrera, Christopher Schutta, Melia Pisano, Marvin J. Grubman, David A. Brake, Timothy Miller, Barbara J. Kamicker, Femi Olutunmbi, Damodar Ettyreddy, Douglas E. Brough, Bryan T. Butman, John G. Neilan,